摘要
目的:观察微粒化非诺贝特治疗糖尿病(DM)血脂异常及其对血清C-反应蛋白(C-RP)的影响.方法:选择1999年1月～2004年12月门诊及住院的2型糖尿病(T2DM)患者共86例,将上述患者随机分成治疗组44例,对照组42例.治疗组给予微粒化非诺贝特200 mg,每晚服用,连续8周;对照组给予辛伐他汀10 mg,每晚服用,连续8周.分别于治疗前和治疗后8周检查血脂常规、C-RP、肝功能、血常规、血糖等指标.结果:治疗组与对照组治疗8周后,血清甘油三脂(TG)明显降低(P＜0.01)、高密度脂蛋白胆固醇(HDL-C)显著增加(P＜0.01),两组比较有显著差异(P＜0.01);两组血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、C-RP均有显著下降(P＜0.01),但两组比较无显著差异(P＞0.05).结论:微粒化非诺贝特治疗糖尿病血脂异常有确切调脂及抗炎作用.
Objective：To observe the effects of micronised fenofibrate on the treatment of diabetes mellitus （DM） dyslipidemia and on the C-reactive protein. Methods：During 1999-01-2004-12,86 patients with T2DM were randomly divided into two groups ：The treatment group（n=14） and the control group（n=42）.The treated group was given 200 microgram of micronised fenofibrate every night for 8 weeks. The control group was given 10 microgram of simvastatin every night for 8 weeks. Compare the TG.TGHDL-CLDL-C and C-RP before treatment and 8 weeks later respectively. Results ：Compared with the control group after 8 weeks treatment,the TG decreased significantly （P〈0.01 ）. The HDL - C increased significantly （ P〈0.01 ） , and there is significantly different between two groups （ P〈0.01）. The TC.LDL-C and C-RP had been decreased significantly （P（0.01）,but were no significantly different between two groups（P〉0.05）. Coclusion：The patients with DM dyslipidemia can be improved by micronised fenofibrate.
出处
《临床医药实践》
2005年第10期737-738,共2页
Proceeding of Clinical Medicine
关键词
微粒化非诺贝特
糖尿病
血脂异常
C反应蛋白
micronised fenofibrate
diabetes melltus
dyslipidemia
C-reactive protein
